Celiac Disease Treatment Market

Celiac Disease Treatment Market Size

The global celiac disease treatment market was estimated at USD 649.9 million in 2024. The market is expected to grow from USD 712.6 million in 2025 to USD 1.7 billion in 2034, at a CAGR of 10.6% during the forecast period. The heighted incidence of celiac disease as well as the growing awareness among healthcare providers regarding the availability of advanced diagnostic products are the major factors that raise the number of people diagnosed with celiac disease, contributing to the demand for effective treatment that boosts market growth. For example, as per the Celiac Disease Foundation report, about 1 in 100 people globally are affected by celiac disease. Therefore, the rising awareness pertaining to disease among people and healthcare professionals has increased the number of target population requiring therapeutic and supportive interventions, boosting market growth.

Additionally, the increasing research and development activities for the development of pharmaceutical treatments options is propelling the growth of celiac disease treatment options during the forecast period. For instance, larazotide acetate which is expected to be launched in the market soon. Moreover, the increasing usage of gluten-free diets, among non-celiac population, with the rising growth of non-invasive diagnostic tools, such as advanced serological tests, has enhanced the accuracy of test with reduced diagnostic time contribute market growth. For example, technologies such as HLA typing and improved antibody testing have increased the testing rates by 8.5% annually. Thus, with the rise in technological advancement in diagnostic, the number of people diagnosed with the disease increases and has resulted in an increase in demand of effective therapeutics options.

The celiac disease treatment market includes the healthcare industry, focused on managing and treating celiac disease. It is a chronic autoimmune disorder activated by the ingestion of gluten in genetically predisposed individuals. The market encompasses a wide variety of pharmaceutical products, supplements, and therapies to reduce the symptoms, prevent complications, and improve the quality of life for affected individuals.

Celiac Disease Treatment Market Trends

The continuous innovation in medicinal therapies such as the development of novel drug delivery systems and therapies such as enzymatic treatments, immune-modulators, and vaccine research is creating new treatment possibilities that foster market growth.

• The potential for new treatment strategies is latiglutenase enzyme therapy, which may reduce gluten toxicity.
  
• In addition, there is significant investment in R&D on targeted treatment options for celiac disease by pharmaceutical companies. For example, Takeda Pharmaceuticals and Innovate Biopharmaceuticals are concentrating on immune-modulating therapies and biologics that are expected to accelerate market growth.
  
• Moreover, the rise in healthcare spending in developed and developing economies enables better access to therapy and diagnosis. Thus, the rise in healthcare spending with insurance coverage for the diagnosis and treatment of celiac disease has increased the adoption of treatment options, thereby driving market growth.
  

Celiac Disease Treatment Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on treatment, the global market is bifurcated into vitamins and minerals supplements, gluten-free diet, and medical therapies. The global market is expected to grow from 484.2 million in 2021 to USD 1.7 billion by the end of 2034. The vitamins and minerals supplements segment dominated the market and was valued at USD 315.1 million in 2024.

• Celiac disease reduces the absorption of iron, calcium, vitamin D, B12, and folate contributing to the damage of the small intestine. Therefore, vitamins and supplements are required to nurture an improved diet, thereby contributing to market growth.
  
• Additionally, vitamins and minerals are important in the treatment of celiac disease as it can help repair the gut lining. Also, patients suffering from celiac disease increases the intake of calcium and vitamin D as these nutrients contribute to moderate bone health which is often a problem in celiac patients because of malabsorption.
  
• Moreover, the market growth is fueled by increasing customer demand for specialized vitamins and minerals products for patients suffering with from this disease. Such products raise consumers’ interest as they support gut health, thereby fostering market growth.
  

Learn more about the key segments shaping this market

Download Free PDF

Based on the route of administration, the global celiac disease treatment market is categorized into oral and parenteral. The oral segment accounted for the highest market share of 63.4% in 2024.

• Oral treatments offer better ease, as patients can easily take them at home without any assistance from healthcare provider or specialized equipment.
  
• Additionally, the advancement of novel oral formulations like enzyme supplements and immune modulators have increased the number of treatment options available for patients. The purpose of these new formulations is to enhance efficacy, bioavailability, and easy absorption of drugs, that in turn are increasing adoption and contributing to market growth.
  
• Furthermore, medication taken orally is usually more convenient than injections and infusions. Most patients prefer oral therapies as they are easy to take, which is favorable for people with tight schedules to take medicine on time, without any requirement of hospital visit. These advantages offered by oral treatment helps with the segmental market growth.
  

Based on the end use, the global celiac disease treatment market is categorized into hospitals, specialty clinics, homecare settings, and other end users. The hospitals segment dominated the market in 2024 and is anticipated to reach USD 904.1 million by 2034.

• Anti-inflammatory drugs and therapeutic vaccines are shaping a new direction in treatment, prompting hospitals to broaden their services and allow incorporation of these drugs in the treatment regime. Additionally, the advancement in diagnostic tools, and the availability of different treatment options in hospital settings have improved the patient’s outcomes leading to market growth.
  
• Additionally, hospitals offer the patients first-line treatments for celiac disease like nutrition therapy, gluten free diet, and biologicals which are not available at primary care centers.
  
• Furthermore, patients’ dependence on biological agents and enzyme increases the number of visits to hospitals. These procedures and therapies often lead to inpatient admissions for further observation which in turn accelerates the market growth.
  

Looking for region specific data?

Download Free PDF

In 2024, the U.S. held a significant position in the North America celiac disease treatment market and was valued at USD 260.3 million.

• The number of cases of celiac disease continues to increase in U.S., led to increasing demand for better treatment options. For instance, as per the report the U.S. represented over 88.4 % of the total North American celiac disease, indicating a very high patient base.
  
• Additionally, the continual medical research into novel treatment approaches and modernized diagnostic systems and therapies is likely to propel market growth. Major companies search for new avenues to differentiate themselves in the market to grow, which is further fostering market growth.
  
• For instance, Zedira’s Larazotide acetate and Immunic’s IMU-838 are trying to mitigate the unwanted immune system reactions in celiac patients, which is one of the most important unmet medical needs.
  

Germany shows strong growth potential in the Europe celiac disease treatment market.

• The increasing prevalence of celiac disease in Germany with supportive regulatory bodies that are actively promoting the control and treatment of disease boosts market growth.
  
• The easy availability of gluten-free products in the country coupled with the increasing demand for dietary minerals and supplements for the management of disease, contribute to market growth.
  
• Furthermore, the increasing research and development activities to introduce novel drugs therapies to offer better safety and efficacy in the treatment has contributed to the demand for celiac disease treatments in the country.
  
• Additionally, the German government and health authorities have been active to educate public through health campaigns about gluten intolerance and celiac disease,  driving further market growth.
  

The celiac disease treatment market in Asia Pacific is estimated to grow at a CAGR of 11% over the next few years.

• The change in dietary habits and increasing adoption of western-style food in the county leads to a rise in celiac disease, that contribute to market growth.
  
• Moreover, the Chinese government has been taking active measures to improve gastrointestinal health, including celiac disease. In addition, increasing funding for research and development programs to improve public health increases the demand for different treatment options including gluten-free diet, boost market growth.
  
• Furthermore, China’s growing international trade and tourism have also contributed to an increase in the impending spread of disease, this necessitating better treatments and awareness contribute market growth.
  

Brazil celiac disease treatment market is projected to witness growth in coming years within the Latin American region.

• Strict regulatory laws by Brazilian government to specify gluten content and increasing consumer preference and awareness for gluten-free and celiac-safe lifestyle, leads to increase in adoption of such products, thereby contributing to market growth.
  
• Furthermore, the availability of proven therapies, for the treatment of celiac disease has positively influenced the market. Additionally, the increasing partnership with global pharmaceutical companies provide access for novel treatment options that has driven its adoption in Brazil.
  

Saudi Arabia is anticipated to grow in the Middle East and African celiac disease treatment market.

• The expansion of specialized clinics and hospitals facilities in Saudi Arabia that offers specialized services for gastrointestinal disease including celiac drives the market growth.
  
• Moreover, Saudi Arabia is collaborating with universities and international research bodies to develop and import innovative celiac disease treatments formulation, thereby fostering market growth.
  
• Furthermore, Saudi Arabia have a high expatriate population that have high risk of celiac prevalence, propelling the demand for gluten-free products thereby contributing to the market growth.
  

Celiac Disease Treatment Market Share

The top players of the market account for approximately 35% of the market share which includes companies such as Teva Pharmaceutical Industries, Amgen, Amneal Pharmaceuticals.  The celiac disease treatment industry is characterized by intense competition among established pharmaceutical companies and emerging players, with competition primarily driven by factors such as pricing strategies, innovative product development, and the introduction of advanced treatment formulations. Companies seek a competitive edge through strategic joint ventures, mergers, and acquisitions, enabling them to expand product portfolios and enhance market penetration.

Moreover, the collaborations with research institutions and investments in R&D further foster the development of novel therapies, addressing unmet medical needs. Additionally, efforts to improve affordability, accessibility, and sustainable practices are key to gaining traction in underserved regions, allowing market players to strengthen their positions globally. Meanwhile, emerging pharmaceutical firms are bringing innovative approaches and targeting novel mechanisms, adding to the market's dynamism and fostering a rapidly evolving ecosystem. This competitive network reflects a collaborative effort to meet the growing demand for effective celiac disease treatments while adapting to the challenges of a dynamic healthcare market.

Celiac Disease Treatment Market Companies

Prominent players operating in the celiac disease treatment industry are as mentioned below:

• ActoBio
• Amgen
• Amneal Pharmaceuticals
• BioLineRx
• Calypso Biotech
• General Mills
• Glenmark Life Sciences
• Hikma Pharmaceuticals
• Innovate Biopharmaceutical
• Novartis
• Takeda Pharmaceutical Company
• Teva Pharmaceutical
• Viatris
• Zydus Pharmaceuticals 
  

Celiac Disease Treatment Industry News

• In September 2024, Barinthus Biotherapeutics announced the initiation of its first-in-human Phase 1 trial of VTP-1000 in adults with celiac disease. The randomized, placebo-controlled clinical trial, which includes a controlled gluten challenge, will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-1000. This product launch in the upcoming year will boost market growth significantly.
  
• In December 2022, Nemysis Ltd and Faran S.A. sign a strategic agreement to cooperate for the development of endopeptidase E40 for celiac disease. This will help to broaden the treatment availability.
  
• In October 2022, Takeda and Dr. Falk Pharma GmbH announced a collaboration and licensing agreement to develop ZED1227/TAK-227, a Phase 2b investigational therapy for the treatment of celiac disease. This product approval in the future marked a significant advancement in the availability of effective treatments for celiac disease.
  

The celiac disease treatment market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment

• Vitamins and minerals supplements
• Gluten-free diet
• Medical therapies

Market, By Route of Administration

• Oral
• Parenteral

Market, By End Use

• Hospitals
• Specialty clinics
• Homecare settings
• Other End Use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE